Kratom Cardiac Arrest and the Limits of a Mitragynine Blood Level
By Forensic Toxicology Working Group Members · September 25, 2026
A blood mitragynine concentration can document exposure and contribute to a causation assessment. It cannot, by itself, determine whether kratom caused a cardiac arrest or whether a concentration would be fatal in another person. A September 2026 case report offers a useful example for expert review.
What the new case report documents
Dunz and colleagues reported a 22-year-old man with asystolic cardiac arrest after reported kratom tea consumption. Targeted mass-spectrometric testing reported blood mitragynine of 500 µg/L, equivalent to 500 ng/mL. The patient underwent resuscitation and survived. The publication is a single case report, published September 23, 2026, rather than a controlled concentration–effect study.
The authors considered mitragynine intoxication the most plausible explanation following investigation of alternative causes. That is a clinical interpretation of the entire case. It should be distinguished from the empirical finding that mitragynine was measured in blood.
Why survival does not settle causation
Survival after resuscitation does not establish that an exposure was safe or incapable of causing death. Treatment changes outcomes. Equally, a concentration observed in some fatalities is not a deterministic threshold that proves causation whenever the same number appears in another case.
A defensible opinion should account for specimen matrix, collection time, treatment, other drugs, and the clinical sequence. Comparing a hospital sample with postmortem concentrations also requires attention to blood collection site, redistribution, and specimen condition. Numerical overlap alone cannot resolve those differences.
Questions to ask before using the paper in an expert report
- When was blood collected relative to collapse, resuscitation, medication, and fluids?
- Was the matrix whole blood, serum, or plasma, and is the comparison matrix the same?
- Which compounds and metabolites were included in the screen, at which reporting limits?
- Were mitragynine and 7-hydroxymitragynine separately measured with demonstrated selectivity?
- Was the consumed product analyzed, and is its dose or alkaloid composition known?
- Does the clinical sequence distinguish a primary cardiac event from seizure, apnea, or another pathway?
What a negative screen can establish
The report describes routine testing followed by targeted mitragynine testing. A negative result must be interpreted against the laboratory’s actual analyte list and validation. It should not be expanded into a statement that every potentially relevant substance was absent. Mass spectrometry is a platform; identification criteria, chromatographic separation, calibration, and quality controls determine the strength of the individual result.
How to use the paper fairly
This case is useful when examining whether an opinion relies too heavily on a concentration table. It also supports considering targeted testing when exposure history and routine results do not align. It does not establish a population risk estimate, a universally fatal level, or proof that kratom could not have caused the reported arrest. The report does not supply a complete analytical validation package or a quantitative 7-OH result.
Research paper and related analysis
Dunz J and colleagues. Sudden cardiac arrest in a young healthy man following kratom tea consumption: a case report and brief literature review. Wiener klinische Wochenschrift. Published September 23, 2026. Read the publisher paper: DOI 10.1007/s00508-026-02826-5. Evidence type: single clinical case; full-text report reviewed.
Continue with kratom and 7-OH evidence and why a positive 7-OH test does not identify a particular product.
